Boston Scientific Corp. (BSX) filed a Form 8K – Director, Officer or Compensation Filing – with the U.S Securities and Exchange Commission on December 01, 2017.
(e) Named Executive Officer Compensation Adjustment
On December 1, 2017, Joseph M. Fitzgerald, our executive vice president and president, Rhythm Management, was granted the option to purchase 306,372 shares of our common stock (having an aggregate value of $2.5 million) at a price of $26.15 per share. The grant vests in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. The grant is made pursuant to the 2011 Boston Scientific Long Term Incentive Plan (“Plan”) and will be subject to all provisions of the applicable award agreements under which it is granted and the Plan.
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/885725/000088572517000047/namedexecutiveofficercompe.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/885725/000088572517000047/0000885725-17-000047-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company’s financial position or the value of its shares.
Copyright (c) 2017 Dow Jones & Company, Inc.